Welcome to our dedicated page for Oramed Pharmaceuticals SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oramed Pharmaceuticals Inc. (ORMP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oramed’s filings reflect its status as a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, and they document both its operating activities and its capital markets transactions.
Current and periodic reports such as Form 8-K detail material events, including option and warrant agreements, restructuring of notes, joint venture terminations, adoption of a Rights Agreement, and dividend declarations. For example, Oramed has filed 8-K reports describing its Option Agreement for the repurchase of Scilex warrants, restructuring of Scilex debt into convertible notes and warrants, the termination of a joint venture agreement with Hefei Tianhui Biotech Co., Ltd., and the adoption of a Rights Agreement that includes a dividend of common stock purchase rights.
Financial reporting is captured in quarterly and annual filings (Forms 10-Q and 10-K), which include Oramed’s financial statements, management’s discussion and analysis, and notes regarding its oral insulin program, POD™ technology development, and diversified investment portfolio. These documents provide context on how investments in entities such as Scilex Holding Company and Alpha Tau Medical Ltd. are reflected in the company’s financial condition and results of operations.
Filings also cover corporate governance and equity compensation, such as amendments to the company’s stock incentive plan and voting results from annual meetings of stockholders, as well as details on Oramed’s common stock registration on The Nasdaq Capital Market and the Tel Aviv Stock Exchange.
On Stock Titan, AI-powered tools summarize key points from Oramed’s 10-K, 10-Q, and 8-K filings, helping users quickly understand complex disclosures, track changes in financing arrangements, and review material agreements. Investors can also monitor updates related to rights plans and other actions that may affect the rights of security holders.
Oramed Pharmaceuticals (ORMP) reported a swing to profitability driven by investment revaluations. For the nine months ended September 30, 2025, net income attributable to stockholders was $54,041 thousand, including third‑quarter net income of $48,395 thousand. Financial income, net, reached $74,278 thousand, reflecting fair value gains primarily on Alpha Tau and Scilex exposures.
Total assets were $220,493 thousand with stockholders’ equity of $203,282 thousand. Cash and cash equivalents were $52,179 thousand. The company recognized $2,000 thousand of revenue tied to the HTIT License Agreement, while cost of revenue of $1,987 thousand related to IIA obligations.
Oramed expanded its investment portfolio: its Alpha Tau stake measured at fair value was $64,803 thousand, and it holds a 50% interest in RoyaltyVest. With Scilex, Oramed received $13,000 thousand from the repurchase of 3,130,000 Subsequent Penny Warrants and retains an option for $14,000 thousand on 3,370,000 additional warrants on or before December 31, 2025. The company also continued a buyback program, repurchasing $732 thousand of shares year‑to‑date.
Oramed Pharmaceuticals (ORMP) repurchased and retired shares and ended a planned joint venture. On October 20, 2025, the company bought back 1,155,367 shares of its common stock from Hefei Tianhui Biotech Co., Ltd. at $2.23 per share for an aggregate $2,576,468.41. The transaction closed the same day, and the shares were cancelled and retired, reducing the share count.
On October 23, 2025, Oramed terminated its Joint Venture Agreement and a related Supplemental Agreement with HTIT after HTIT was unable to satisfy closing conditions. The company also furnished a shareholder letter with preliminary, unaudited financial information as of September 30, 2025, accompanied by cautionary language noting that results are subject to adjustment and may materially vary.
Oramed Pharmaceuticals Inc. reported that Scilex Holding Company exercised the first tranche of an option to repurchase warrants Oramed holds in Scilex. These warrants allow purchase of Scilex common stock. On September 30, 2025, Scilex repurchased warrants covering 3,130,000 Scilex shares from Oramed for $13,000,000, as part of a previously agreed warrant repurchase transaction totaling up to $27,000,000. Under the option agreement, Scilex may still repurchase the remaining warrants covering 3,370,000 Scilex shares from Oramed for $14,000,000 on or before December 31, 2025.
Oramed Pharmaceuticals insider amendment outlines updated beneficial ownership and equity awards for reporting person Nadav Kidron. Mr. Kidron reports beneficial ownership of 3,116,729 shares, representing approximately 7.6% of the company’s outstanding common stock based on 41,003,600 shares outstanding. The filing discloses 762,750 stock options exercisable or issuable within 60 days, 63,541 RSUs vesting within 60 days, 73,500 vested-but-not-issued RSUs and 218,603 shares held by a former director, Xiaopeng Li. The amendment details grants since the original Schedule 13D, including RSU and PSU awards with specified vesting events and that certain PSUs vested on February 11, 2025.
Oramed Pharmaceuticals Inc. is registering an additional 2,000,000 shares of its common stock under its Amended and Restated 2019 Stock Incentive Plan. These shares may be issued in the future as equity awards to employees, directors, and other service providers, aligning their compensation with the company’s stock performance.
This new Form S-8 follows earlier registrations of 1,000,000 shares in 2019, 2,000,000 shares in 2020, and 4,500,000 shares in 2022 for the same plan. The filing also incorporates by reference the company’s latest annual, quarterly, and current reports, so investors can rely on those documents for updated information about Oramed’s business and financial condition.
Oramed Pharmaceuticals Inc. reported results of its 2025 annual stockholders meeting held on August 19, 2025. Stockholders approved an amendment to the company’s Amended and Restated 2019 Stock Incentive Plan, increasing the total number of shares of common stock authorized for issuance under the plan by 2,000,000 shares to 9,500,000 shares. This plan is used to grant equity awards to eligible participants, including officers and directors.
All nominated directors were re-elected to serve until the next annual meeting, with each receiving over 12.4 million votes in favor, subject to varying levels of opposition and broker non-votes. Stockholders also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the company’s independent registered public accounting firm for the 2025 fiscal year.
Oramed Pharmaceuticals, Inc. reports condensed consolidated interim results and disclosures for the quarter ended June 30, 2025. The company operates in a single reportable segment focused on research and development of orally delivered pharmaceuticals and vaccines. The filing details multiple strategic investments and financing arrangements, including a $36,900 investment in Alpha Tau Medical (yielding an unrealized gain of $7,138 recognized in the six months ended June 30, 2025), equity method accounting for a 50% interest in RoyaltyVest, and various loans and real estate investments presented at fair value.
The company continues to hold structured receivables and convertible notes related to Scilex, including Tranche A and Tranche B Notes, and warrants (including 6,500,000 Subsequent Penny Warrants) with monetization restrictions; as of June 30, 2025 Scilex had repaid $69,200 of the Tranche A Note. The company entered an Option Agreement (July 22, 2025) under which Scilex may repurchase Subsequent Penny Warrants for a total of $27,000, and the agreement could extend the Tranche A Note maturity if completed. The company discloses deferred revenue recognition related to an HTIT license arrangement and describes cash flows, fair value measurements, share-based compensation grants (PSUs/RSUs), and a limited stock repurchase program under which 163,869 shares were repurchased for $371.
Oramed Pharmaceuticals (ORMP) filed an 8-K disclosing an Option Agreement signed 22-Jul-25 with Scilex Holding. The accord gives Scilex the right to repurchase Oramed’s remaining 6.5 M “Penny Warrants” (exercise price $0.01/sh) in two tranches for a total cash consideration of $27 M. To secure the option, Scilex will pay Oramed $1.5 M in two equal installments due 8-Aug-25 and 16-Dec-25.
- Tranche 1: up to 3.13 M warrants for $13 M if exercised by 30-Sep-25.
- Tranche 2: up to 3.37 M warrants for $14 M if exercised by 31-Dec-25.
If Scilex completes the repurchase and makes all payments, the maturity of the $101.9 M Tranche A senior secured note held by Oramed will be extended to 31-Mar-26 and its make-whole prepayment penalty waived.
Until the earlier of option expiry or termination, Oramed has agreed not to exercise the warrants. Oramed can terminate the agreement if Scilex misses any payment or fails to exercise by the set dates. Post-termination, Scilex will seek shareholder approval to permit stock issuance above a 19.9 % cap should Oramed later exercise retained warrants.
The filing also clarifies prior disclosure: despite Scilex’s 1-for-35 reverse split, the Penny Warrant exercise price remains $0.01 and the quantity remains 6.5 M shares; no impact to previously reported Q1-25 financials.